<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04182321</url>
  </required_header>
  <id_info>
    <org_study_id>960-2019-84</org_study_id>
    <nct_id>NCT04182321</nct_id>
  </id_info>
  <brief_title>Adding Metformin to the Standard Treatment for Patients With HBeAg-Negative Chronic Hepatitis B</brief_title>
  <official_title>Adding Metformin to the Standard Treatment for Patients With HBeAg-Negative Chronic Hepatitis B: A Single-Center, Randomized, Placebo-Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fu-Sheng Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jinan Military General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing 302 Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, placebo-controlled pilot study to assess the efficacy
      and safety of adding Metformin to the standard treatment for patients with HBeAg-positive
      chronic hepatitis B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, placebo-controlled pilot study to assess the efficacy
      and safety of adding Metformin to the standard treatment for patients with HBeAg-positive
      chronic hepatitis B. Sixty subjects who meet the eligibility criteria will be randomized to
      the experimental arm and comparator arm according to a 1:1 ratio. The participants in the
      experimental arm will be treated with Metformin (sustained release tablet, 1000 mg, once a
      day(QD), 24 weeks) and Entecavir (tablet, 0.5 mg, QD, ongoing treatment). The participants in
      the comparator arm will be treated with Placebo (two tablets, QD, 24 weeks) and Entecavir
      (tablet, 0.5 mg, QD, ongoing treatment). The primary endpoint for efficacy assessment is the
      cumulative rate of HBsAg loss at week 36 after enrollment; the secondary endpoint for
      efficacy assessment is the decrease in quantitative HBsAg from the baseline at week 36 after
      enrollment. The secondary endpoint for safety assessment is the cumulative incidence of
      adverse events at week 36 after enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Rate of HBsAg Loss</measure>
    <time_frame>Week 36 after enrollment</time_frame>
    <description>HBsAg Loss is defined as disappearance of HBsAg in patients with chronic hepatitis B during treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in Quantitative HBsAg from the Baseline</measure>
    <time_frame>Week 36 after enrollment</time_frame>
    <description>Quantitative HBsAg is a quantitative indicator reflecting HBsAg level in patients with chronic hepatitis B during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Adverse Events</measure>
    <time_frame>Week 36 after enrollment</time_frame>
    <description>Adverse Event is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation subject administered study drug and that does not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adding Metformin to the standard treatment for patients with HBeAg-negative chronic hepatitis B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The standard treatment for patients with HBeAg-negative chronic hepatitis B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin &amp; Entecavir</intervention_name>
    <description>Metformin (sustained release tablet, 1000 mg, QD, 24 weeks) and Entecavir (tablet, 0.5 mg, QD, ongoing treatment)</description>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo &amp; Entecavir</intervention_name>
    <description>Placebo (two tablets, QD, 24 weeks) and Entecavir (tablet, 0.5 mg, QD, ongoing treatment)</description>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HBeAg negative chronic hepatitis B

          -  Ongoing treatment with Entecavir for more than 12 months

          -  HBV DNA &lt; 500 IU/mL

          -  Quantitative HBsAg &lt; 1000 IU/mL

          -  Alanine aminotransferase (ALT) &lt; 2 Ã— upper limit of normal (ULN)

          -  Agreed to take contraceptive measures during participation for women of a fertile age

          -  Agreed not to engage in other clinical trials during participation

          -  Understood and signed the informed consent form before taking any steps related to
             this study

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Alcoholic liver disease

          -  Drug-induced liver damage

          -  Autoimmune liver disease

          -  Liver cirrhosis

          -  Liver cancer

          -  Liver transplantation

          -  Pregnant or lactating women

          -  Other conditions judged by investigators unsuitable for participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fu-Sheng Wang</last_name>
    <role>Study Chair</role>
    <affiliation>The Fifth Medical Center of Chinese PLA General Hospital (Beijing 302 Hospital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fu-Sheng Wang</last_name>
    <phone>+8613671005510</phone>
    <email>fswang302@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuanyuan Li</last_name>
    <phone>+8618611839069</phone>
    <email>lyy020818@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The 960 Hospital of Chinese PLA Joint Support Force (Jinan Military General Hospital)</name>
      <address>
        <city>Tai'an</city>
        <state>Shandong</state>
        <zip>271000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qinghua Shang</last_name>
      <phone>+8615505486767</phone>
      <email>shangqh@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Wei Zhang</last_name>
      <phone>+8615505386060</phone>
      <email>15505386060@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Qinghua Shang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2019</study_first_posted>
  <last_update_submitted>March 14, 2020</last_update_submitted>
  <last_update_submitted_qc>March 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing 302 Hospital</investigator_affiliation>
    <investigator_full_name>Fu-Sheng Wang</investigator_full_name>
    <investigator_title>Study Chair</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Entecavir</keyword>
  <keyword>hepatitis B virus (HBV)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

